Lenacapavir, a once-a-year injection, can treat HIV, prevent transmission and stop new infections — all with a single shot.

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 - but only if between two and ...

A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 — but only if between two and four million HIV-negative people in the country would need to use ...

Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. | Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. The PMCPA ruled the ...

The number of employees laid off dropped year over year during the first quarter. BioSpace recaps the five largest layoffs, ...

While plans for global access to lenacapavir, the twice-yearly injectable PrEP product which demonstrated extraordinary efficacy last year, have progressed unusually quickly, critics say that the ...